Key Drivers
- Heavy leverage
- Margin resilience
- Quarterly losses
AIAI Summary
MNKD is now a real commercial business with upside from Furoscix growth, ralinepag royalties, and the Afrezza pediatric catalyst, but the core takeaway is that profitability and cash generation remain fragile because operating expenses can quickly outrun gross profit, keeping dilution and leverage the main investment risk until the company proves durable quarterly operating discipline.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Heavy leverage
- •Margin resilience
- •Quarterly losses
MNKD's full-year profitability and cash generation were solid, but the latest quarter showed a sharp deterioration with operating and net losses, while negative equity and heavy debt make leverage the key risk.
Price Behavior
Key Price Behavior Insights:
- •Trend intact
- •Profit-taking drift
- •Support watch
MNKD's trend remains positive over the last month, but the pullback from $3.56 to near $3.09 leaves it vulnerable unless it reclaims the low-$3.30s and holds $3.00 support.
Sharp run to $3.56 on 2026-05-06 was followed by a steady pullback
Sentiment & News
Key News Insights:
- •Earnings miss
- •Ralinepag partnership
- •Competitive pressure
MannKind reported a wider-than-expected Q1 2026 loss, announced a new ralinepag dry powder partnership with United Therapeutics, and flagged ongoing margin and competitive pressure as growth increasingly relies on smaller assets.
The update is modestly negative for the instrument, as pipeline progress is being offset by weaker earnings, margin pressure, and royalty competition risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings